NY A 500
in committeeEstablishes a generic drug research and development laboratory and production facility and the empire state biosimilar insulin initiative
New York · 2025-2026 Regular Session · lower
Description
Establishes a generic drug research and development laboratory and production facility to manufacture generic prescription drugs in the state and the empire state biosimilar insulin initiative, which will develop generic forms of the three most widely used forms of insulin.
- Introduced
- —
- Status date
- —
- Latest action
- 2026-01-07 — REFERRED TO HEALTH
- Bill type
- bill
- Last updated
- —
Sponsors
- Phil Steckprimary
Committees
Not provided by source.
Action timeline
2025-01-08
REFERRED TO HEALTH
referral-committee
2026-01-07
REFERRED TO HEALTH
referral-committee
Versions
- A500Compare
Documents
- text/html(no extracted text yet)
- application/pdf
Votes
Not provided by source.
Related bills
- Prior session: A 9535
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=A 500. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
- Some documents have no extracted text yet, so version comparison may be limited.
See the methodology page for data sources and limitations.